Молекулярные маркеры чувствительности и резистентности карцином толстой кишки к терапии антагонистами EGFR

Молекулярные маркеры чувствительности и резистентности карцином толстой кишки к терапии антагонистами EGFR

Автор: Иванцов А.О., Янус Г.А., Суспицын Е.Н., Анисимова Е.Н., Имянитов Е.Н.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 1 (73), 2016 года.

Бесплатный доступ

Таргетная терапия метастатического рака толстой кишки отличается отсутствием молекулярных маркеров, позволяющих предсказать наличие выраженной чувствительности к специфическому ле- чению. Вместе с тем для анти-EGFR антител известны надежные маркеры резистентности к терапии. Их определение стало обязательной процедурой, предшествующей назначению соответствующих лекарственных препаратов. «Золотым стандартом» сегодняшнего дня, обозначенным в различных клинических рекомендациях, является анализ всей кодирующей последовательности генов KRAS и NRAS в опухолевой ткани. Мутации в KRAS и NRAS встречаются в 45-65 % карцином толстой кишки. Тем не менее исключение пациентов, в чьих опухолях были обнаружены мутации KRAS и NRAS, не решает полностью проблему отбора больных. Это стимулирует поиск новых предиктивных маркеров. К настоящему моменту практически доказана предиктивная роль мутаций V600E в гене BRAF. Интенсивно изучается роль мутаций и/или нарушений экспрессии генов PIK3CA, PTEN, EREG, AREG, IGF2, а также амплификаций HER2/neu и MET. Ожидается, что работы в данном направлении позволят существенно повысить клиническую и экономическую эффективность лечения рака толстой кишки.

Еще

Аденокарцинома, рак толстой кишки, анти-egfr антитела, предиктивные маркеры

Короткий адрес: https://sciup.org/14056786

IDR: 14056786   |   DOI: 10.21294/1814-4861-2016-15-1-59-66

Список литературы Молекулярные маркеры чувствительности и резистентности карцином толстой кишки к терапии антагонистами EGFR

  • Ålgars A., Lintunen M., Carpén O., Ristamäki R., Sundström J. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer//Br. J. Cancer. 2011. Vol. 105 (2). P. 255-262 DOI: 10.1038/bjc.2011.223
  • Ahronian L.G., Sennott E.M., Van Allen E.M., Wagle N., Kwak E.L., Faris J.E., Godfrey J.T., Nishimura K., Lynch K.D., Mermel C.H., Lockerman E.L., Kalsy A., Gurski J.M. Jr., Bahl S., Anderka K., Green L.M., Lennon N.J., Huynh T.G., Mino-Kenudson M., Getz G., Dias-Santagata D., Iafrate A.J., Engelman J.A., Garraway L.A., Corcoran R.B. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations//Cancer Discov. 2015. Vol. 5 (4). P. 358-367 DOI: 10.1158/2159-8290.CD-14-1518
  • Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer//J. Clin. Oncol. 2008. Vol. 26 (10). P. 1626-1634 DOI: 10.1200/JCO.2007.14.7116
  • Arena S., Bellosillo B., Siravegna G., Martínez A., Cañadas I., Lazzari L., Ferruz N., Russo M., Misale S., González I., Iglesias M., Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sánchez J., Dalmases A., Bellmunt J., De Fabritiis G., Rovira A., Di Nicolantonio F., Albanell J., Bardelli A., Montagut C. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer//Clin. Cancer Res. 2015. Vol. 21 (9). P. 2157-2166. CCR-14-2821 DOI: 10.1158/1078-0432
  • Barber T.D., Vogelstein B., Kinzler K.W., Velculescu V.E. Somatic mutations of EGFR in colorectal cancers and glioblastomas//N. Engl. J. Med. 2004. Vol. 351 (27). P. 2883.
  • Bardelli A., Corso S., Bertotti A., Hobor S., Valtorta E., Siravegna G., Sartore-Bianchi A., Scala E., Cassingena A., Zecchin D., Apicella M., Migliardi G., Galimi F., Lauricella C., Zanon C., Perera T., Veronese S., Corti G., Amatu A., Gambacorta M., Diaz L.A. Jr., Sausen M., Velculescu V.E., Comoglio P., Trusolino L., Di Nicolantonio F., Giordano S., Siena S. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer//Cancer Discov. 2013. Vol. 3 (6). P. 658-673 DOI: 10.1158/2159-8290
  • Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies//Cancer Res. 2007. Vol. 67 (6). P. 2643-2648.
  • Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer//Nature. 2012. Vol. 487 (7407). P. 330-337 DOI: 10.1038/nature11252
  • Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry//J. Clin. Oncol. 2005. Vol. 23 (9). P. 1803-1810.
  • Cremolini C., Di Bartolomeo M., Amatu A., Antoniotti C., Moretto R., Berenato R., Perrone F., Tamborini E., Aprile G., Lonardi S., Sartore-Bianchi A., Fontanini G., Milione M., Lauricella C., Siena S., Falcone A., de Braud F., Loupakis F., Pietrantonio F. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis//Ann. Oncol. 2015. Vol. 26 (10). P. 2092-2097 DOI: 10.1093/annonc/mdv290
  • De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent- Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T., Di Fiore F., Gangloff A.O., Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis // Lancet Oncol. 2010. Vol. 11 (8). P. 753-762 DOI: 10.1016/S1470-2045(10)70130-3
  • Disel U., Germain A., Yilmazel B., Abali H., Bolat F.A., Yelensky R., Elvin J.A., Lipson D., Chmielecki J., Wang K., Stephens P.J., Ross J.S., Miller V.A., Ali S.M., George T.J. Jr. Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification//Oncoscience. 2015. Vol. 2 (6). P. 581-584.
  • Fakih M.G. Metastatic colorectal cancer: current state and future directions//J. Clin Oncol. 2015. Vol. 33 (16). P. 1809-1824. doi: 10.1200/JCO.2014.59.7633.
  • Flanagan J.U., Shepherd P.R. Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme//Biochem. Soc. Trans. 2014. Vol. 42 (1). P. 120-124 DOI: 10.1042/BST20130255
  • Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., Ding M., Bamford S., Cole C., Ward S., Kok C.Y., Jia M., De T., Teague J.W., Stratton M.R., McDermott U., Campbell P.J. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer//Nucleic Acids Res. 2015. Vol. 43 (Database issue). P. D805-811 DOI: 10.1093/nar/gku1075
  • Frattini M., Saletti P., Romagnani E., Martin V., Molinari F., Ghisletta M., Camponovo A., Etienne L.L., Cavalli F., Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients//Br. J. Cancer. 2007. Vol. 97 (8). P. 1139-1145.
  • Haley L., Tseng L.H., Zheng G., Dudley J., Anderson D.A., Azad N.S., Gocke C.D., Eshleman J.R., Lin M.T. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers//Mod. Pathol. 2015. Vol. 28 (10). P. 1390-1399 DOI: 10.1038/modpathol.2015.86
  • Hecht J.R., Douillard J.Y., Schwartzberg L., Grothey A., Kopetz S., Rong A., Oliner K.S., Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer//Cancer Treat. Rev. 2015. Vol. 41 (8). P. 653-659. doi: 10.1016/j. ctrv.2015.05.008.
  • Hobor S., Van Emburgh B.O., Crowley E., Misale S., Di Nicolantonio F., Bardelli A. TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells//Clin. Cancer Res. 2014. Vol. 20 (24). P. 6429-6438. CCR-14-0774 DOI: 10.1158/1078-0432
  • Huang L., Liu Z., Deng D., Tan A., Liao M., Mo Z., Yang X. Antiepidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients//Arch. Med. Sci. 2014. Vol. 10 (1). P. 1-9 DOI: 10.5114/aoms.2014.40728
  • Hutchinson R.A., Adams R.A., McArt D.G., Salto-Tellez M., Jasani B., Hamilton P.W. Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer//J. Transl. Med. 2015. Vol. 13. P. 217 DOI: 10.1186/s12967-015-0531-z
  • Italiano A., Follana P., Caroli F.X., Badetti J.L., Benchimol D., Garnier G., Gugenheim J., Haudebourg J., Keslair F., Lesbats G., Lledo G., Roussel J.F., Pedeutour F., François E. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number//Ann. Surg. Oncol. 2008. Vol. 15 (2). P. 649-654.
  • Jiang Z., Li C., Li F., Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis//PLoS One. 2013. Vol. 8, № 2. P. e56205 DOI: 10.1371/journal.pone.0056205
  • Karapetis C.S., Khambata-Ford S., Jonker D.J., O’Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer//N. Engl. J. Med. 2008. Vol. 359 (17). P. 1757-1765. doi: 10.1056/NEJMoa0804385.
  • Kavuri S.M., Jain N., Galimi F., Cottino F., Leto S.M., Migliardi G., Searleman A.C., Shen W., Monsey J., Trusolino L., Jacobs S.A., Bertotti A., Bose R. HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment//Cancer Discov. 2015. Vol. 5 (8). P. 832-841 DOI: 10.1158/2159-8290.CD-14-1211
  • Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbi-son C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris H.A. 3rd, Poplin E.A., Hidalgo M., Baselga J., Clark E.A., Mauro D.J. Expression of epiregulin and amphi-regulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab//J. Clin Oncol. 2007. Vol. 25 (22). P. 3230-3237.
  • Kidess E., Heirich K., Wiggin M., Vysotskaia V., Visser B.C., Marziali A., Wiedenmann B., Norton J.A., Lee M., Jeffrey S.S., Poultsides G.A. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform//Oncotarget. 2015. Vol. 6 (4). P. 2549-2561.
  • Kloth M., Ruesseler V., Engel C., Koenig K., Peifer M., Mariotti E., Kuenstlinger H., Florin A., Rommerscheidt-Fuss U., Koitzsch U., Wodtke C., Ueckeroth F., Holzapfel S., Aretz S., Propping P., Loeffler M., Merkelbach-Bruse S., Odenthal M., Friedrichs N., Heukamp L.C., Zander T., Buettner R. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer//Gut. 2015. pii: Gutjnl-2014-309026 DOI: 10.1136/gutjnl-2014-309026
  • Laurent-Puig P., Pekin D., Normand C., Kotsopoulos S.K., Nizard P., Perez-Toralla K., Rowell R., Olson J., Srinivasan P., Le Corre D., Hor T., El Harrak Z., Li X., Link D.R., Bouché O., Emile J.F., Landi B., Boige V., Hutchison J.B., Taly V. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy//Clin. Cancer Res. 2015. Vol. 21 (5). P. 1087-1097 DOI: 10.1158/1078-0432.CCR-14-0983
  • Lièvre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Côté J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer//Cancer Res. 2006. Vol. 66 (8). P. 3992-3995.
  • Llosa N.J., Cruise M., Tam A., Wicks E.C., Hechenbleikner E.M., Taube J.M., Blosser R.L., Fan H., Wang H., Luber B.S., Zhang M., Papadopoulos N., Kinzler K.W., Vogelstein B., Sears C.L., Anders R.A., Pardoll D.M., Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints//Cancer Discov. 2015. Vol. 5 (1). P. 43-51 DOI: 10.1158/2159-8290.CD-14-0863
  • Llovet P., Sastre J., Ortega J.S., Bando I., Ferrer M., García-Alfonso P., Donnay O., Carrato A., Jiménez A., Aranda E., León A., Grávalos C., Cámara J.C., Feliú J., Sanchíz B., Caldés T., Díaz-Rubio E. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy//Mol. Diagn. Ther. 2015. Vol. 19 (6). P. 397-408. doi: 10.1007/s40291-015-0165-0.
  • Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., Masi G., Stasi I., Canestrari E., Rulli E., Floriani I., Bencardino K., Galluccio N., Catalano V., Tonini G., Magnani M., Fontanini G., Basolo F., Falcone A., Graziano F. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer//Br. J. Cancer. 2009. Vol. 101 (4). P. 715-721 DOI: 10.1038/sj.bjc.6605177
  • Montagut C., Dalmases A., Bellosillo B., Crespo M., Pairet S., Iglesias M., Salido M., Gallen M., Marsters S., Tsai S.P., Minoche A., Seshagiri S., Serrano S., Himmelbauer H., Bellmunt J., Rovira A., Settleman J., Bosch F., Albanell J. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer//Nat. Med. 2012. Vol. 18 (2). P. 221-223 DOI: 10.1038/nm.2609
  • Morelli M.P., Overman M.J., Dasari A., Kazmi S.M., Mazard T., Vilar E., Morris V.K., Lee M.S., Herron D., Eng C., Morris J., Kee B.K., Janku F., Deaton F.L., Garrett C., Maru D., Diehl F., Angenendt P., Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment//Ann. Oncol. 2015. Vol. 26 (4). P. 731-736. doi: 10.1093/annonc/mdv005.
  • Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study//Lancet Oncol. 2005. Vol. 6 (5). P. 279-286.
  • Ooi A., Takehana T., Li X., Suzuki S., Kunitomo K., Iino H., Fujii H., Takeda Y., Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study//Mod. Pathol. 2004. Vol. 17 (8). P. 895-904.
  • Peeters M., Douillard J.Y., Van Cutsem E., Siena S., Zhang K., Williams R., Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab//J. Clin. Oncol. 2013. Vol. 31 (6). P. 759-765 DOI: 10.1200/JCO.2012.45.1492
  • Pietrantonio F., Petrelli F., Coinu A., Di Bartolomeo M., Borgonovo K., Maggi C., Cabiddu M., Iacovelli R., Bossi I., Lonati V., Ghilardi M., de Braud F., Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis//Eur. J. Cancer. 2015. Vol. 51 (5). P. 587-594. doi: 10.1016/j. ejca.2015.01.054.
  • Piton N., Lonchamp E., Nowak F., Sabourin J.C.; KRAS group. Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping//Cancer Epidemiol. Biomarkers Prev. 2015. Vol. 24 (9). P. 1416-1418. EPI-15-0059 DOI: 10.1158/1055-9965
  • Razis E., Pentheroudakis G., Rigakos G., Bobos M., Kouvatseas G., Tzaida O., Makatsoris T., Papakostas P., Bai M., Goussia A., Samantas E., Papamichael D., Romanidou O., Efstratiou I., Tsolaki E., Psyrri A., De Roock W., Bafaloukos D., Klouvas G., Tejpar S., Kalogeras K.T., Pectasides D., Fountzilas G. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab//J. Cancer Res. Clin. Oncol. 2014. Vol. 140 (5). P. 737-748 DOI: 10.1007/s00432-014-1626-2
  • Rowland A., Dias M.M., Wiese M.D., Kichenadasse G., McKinnon R.A., Karapetis C.S., Sorich M.J. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer//Br. J. Cancer. 2015. Vol. 112 (12). P. 1888-1894 DOI: 10.1038/bjc.2015.173
  • Saltz L.B., Meropol N.J., Loehrer P.J. Sr., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor//J. Clin. Oncol. 2004. Vol. 22 (7). P. 1201-1208.
  • Sartore-Bianchi A., Fieuws S., Veronese S., Moroni M., Personeni N., Frattini M., Torri V., Cappuzzo F., Vander Borght S., Martin V., Skokan M., Santoro A., Gambacorta M., Tejpar S., Varella-Garcia M., Siena S. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study//J. Clin. Pathol. 2012. Vol. 65 (3). P. 218-223 DOI: 10.1136/jclinpath-2011-200353
  • Seo Y., Ishii Y., Ochiai H., Fukuda K., Akimoto S., Hayashida T., Okabayashi K., Tsuruta M., Hasegawa H., Kitagawa Y. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer//Oncol. Rep. 2014. Vol. 31 (5). P. 2115-2122. doi: 10.3892/or.2014.3077.
  • Seppälä T.T., Böhm J.P., Friman M., Lahtinen L., Väyrynen V.M., Liipo T.K., Ristimäki A.P., Kairaluoma M.V., Kellokumpu I.H., Kuopio T.H., Mecklin J.P. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer//Br. J. Cancer. 2015. Vol. 112 (12). P. 1966-1975 DOI: 10.1038/bjc.2015.160
  • Sorich M.J., Wiese M.D., Rowland A., Kichenadasse G., McKinnon R.A., Karapetis C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials//Ann Oncol. 2015. Vol. 26 (1). P. 13-21 DOI: 10.1093/annonc/mdu378
  • Valtorta E., Misale S., Sartore-Bianchi A., Nagtegaal I.D., Paraf F., Lauricella C., Dimartino V., Hobor S., Jacobs B., Ercolani C., Lamba S., Scala E., Veronese S., Laurent-Puig P., Siena S., Tejpar S., Mottolese M., Punt C.J., Gambacorta M., Bardelli A., Di Nicolantonio F. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy//Int. J. Cancer. 2013. Vol. 133 (5). P. 1259-1265 DOI: 10.1002/ijc.28106
  • Westwood M., van Asselt T., Ramaekers B., Whiting P., Joore M., Armstrong N., Noake C., Ross J., Severens J., Kleijnen J. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis//Health Technol. Assess. 2014. Vol. 18 (62). P. 1-132 DOI: 10.3310/hta18620
  • Yang Z.Y., Shen W.X., Hu X.F., Zheng D.Y., Wu X.Y., Huang Y.F., Chen J.Z., Mao C., Tang J.L. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis//J. Hematol. Oncol. 2012. Vol. 5. P. 52.
  • Yang Z.Y., Wu X.Y., Huang Y.F., Di M.Y., Zheng D.Y., Chen J.Z., Ding H., Mao C., Tang J.L. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis//Int. J. Cancer. 2013. Vol. 133 (8). P. 1914-1925 DOI: 10.1002/ijc.28153
  • Yanus G.A., Belyaeva A.V., Ivantsov A.O., Kuligina E.Sh., Suspitsin E.N., Mitiushkina N.V., Aleksakhina S.N., Iyevleva A.G., Zaitseva O.A., Yatsuk O.S., Gorodnova T.V., Strelkova T.N., Efremova S.A., Lepenchuk A.Y., Ochir-Garyaev A.N., Paneyah M.B., Matsko D.E., Togo A.V., Imyanitov E.N. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients//Med. Oncol. 2013. Vol. 30 (3). P. 686 DOI: 10.1007/s12032-013-0686-5
  • Yonesaka K., Zejnullahu K., Okamoto I., Satoh T., Cappuzzo F., Souglakos J., Ercan D., Rogers A., Roncalli M., Takeda M., Fujisaka Y., Philips J., Shimizu T., Maenishi O., Cho Y., Sun J., Destro A., Taira K., Takeda K., Okabe T., Swanson J., Itoh H., Takada M., Lifshits E., Okuno K., Engelman J.A., Shivdasani R.A., Nishio K., Fukuoka M., Varella-Garcia M., Nakagawa K., Jänne P.A. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab//Sci. Transl. Med. 2011. Vol. 3 (99). P. 99ra86 DOI: 10.1126/scitranslmed.3002442
  • Zanella E.R., Galimi F., Sassi F., Migliardi G., Cottino F., Leto S.M., Lupo B., Erriquez J., Isella C., Comoglio P.M., Medico E., Tejpar S., Budinská E., Trusolino L., Bertotti A. IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies//Sci. Transl. Med. 2015. Vol. 7 (272). P. 272ra12 DOI: 10.1126/scitranslmed.3010445
Еще
Статья научная
SciUp 2024 © 2024 ©